Published in

Dove Press, Drug Design, Development and Therapy, p. 325

DOI: 10.2147/dddt.s31064

Links

Tools

Export citation

Search in Google Scholar

Current and emerging pharmacological treatments for sarcoidosis: a review

Journal article published in 2013 by Kerry Barba, Scott H. Beegle, Marc A. Judson ORCID, Romel Gobunsuy
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Scott H Beegle,1 Kerry Barba,2 Romel Gobunsuy,1 Marc A Judson1 1Division of Pulmonary and Critical Care Medicine, 2Department of Medicine, Albany Medical College, Albany, NY, USA Abstract: The treatment of sarcoidosis is not standardized. Because sarcoidosis may never cause significant symptoms or organ dysfunction, treatment is not mandatory. When treatment is indicated, oral corticosteroids are usually recommended because they are highly likely to be effective in a relative short period of time. However, because sarcoidosis is often a chronic condition, long-term treatment with corticosteroids may cause significant toxicity. Therefore, corticosteroid sparing agents are often indicated in patients requiring chronic therapy. This review outlines the indications for treatment, corticosteroid treatment, and corticosteroid sparing treatments for sarcoidosis. Keywords: pulmonary sarcoidosis, extrapulmonary sarcoidosis, treatment, drugs, corticosteroids